Matinas BioPharma Holdings (MTNB) Other Non Operating Income (2020 - 2026)
Matinas BioPharma Holdings (MTNB) reported Other Non Operating Income of $15000.0 for Q1 2026, up 475.0% year-over-year from $2608.7 in Q1 2025, and up 106.28% quarter-over-quarter from -$239000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Other Non Operating Income (2020 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 7 years of Other Non Operating Income data on file, last reported at $15000.0 in Q1 2026.
- Other Non Operating Income for Q1 2026 came in at $15000.0, up 475.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$242000.0 (down 235.96% YoY), and the FY2025 annual result was -$261000.0, down 199.62% from the prior year.
- Other Non Operating Income advanced to $15000.0 in Q1 2026 per MTNB's latest filing, from -$239000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $120000.0 in Q2 2024 and troughed at -$239000.0 in Q4 2025.
- A 5-year average of $26822.8 and a median of $45000.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income soared 7895.95% in 2023, then slumped 443.18% in 2025.
- A 5-year view of Other Non Operating Income shows it stood at $89000.0 in 2022, then changed by 0.0% to $89000.0 in 2023, then sank by 149.44% to -$44000.0 in 2024, then tumbled by 443.18% to -$239000.0 in 2025, then soared by 106.28% to $15000.0 in 2026.
- Business Quant data shows MTNB's Other Non Operating Income at $15000.0 in Q1 2026, -$239000.0 in Q4 2025, and $45000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | -239,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -44,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Dec 31, 2022 | 89,000.00 |
| Sep 30, 2022 | 988.00 |
| Jun 30, 2022 | 2,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 15,702.00 |
| Sep 30, 2021 | 41,394.00 |
| Jun 30, 2021 | -1,415.00 |